Pre-exposure Prophylaxis for Prevention of HIV Infection Clinical Trial
Official title:
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
This is a prospective, 3-year observational study to describe drug utilization in uninfected
individuals (UIs) who initiate emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)
(Truvada®) for a pre-exposure prophylaxis (PrEP) indication.
An electronic source of pharmacy/medical encounter information will be used to assess the
demographics and other characteristics of the subjects prescribed FTC/TDF or its components
in a prospective fashion. The data provider will supply all the de-identified information
regarding each visit/interaction that the subject has had with the health system and all the
diagnoses and medications that the UI has had prospectively and retrospectively for the
length of time captured by the source selected.
200 physicians who prescribe FTC/TDF for a PrEP indication will be sampled from the same
source.
n/a